Recombinant human LFA-3-antibody fusion protein (Taizhou Mabtech Pharmaceutical)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human LFA-3-antibody fusion protein (Taizhou Mabtech Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLymphocyte function-associated antigen 3 inhibitors
TargetsLymphocyte function-associated antigen 3
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesTaizhou Maibo Taike Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Maibo Taike Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A